Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Sage Therapeutics Inc (NASDAQ: SAGE) closed at $6.94 down -1.98% from its previous closing price of $7.08. In other words, the price has decreased by -$1.98 from its previous closing price. On the day, 2.06 million shares were traded. SAGE stock price reached its highest trading level at $7.105 during the session, while it also had its lowest trading level at $6.71.
Ratios:
For a deeper understanding of Sage Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.02 and its Current Ratio is at 10.02. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on October 04, 2024, whereas the target price for the stock was revised from $10 to $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 10 ’24 when JONAS JEFFREY M bought 7,500 shares for $5.53 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SAGE now has a Market Capitalization of 424542720 and an Enterprise Value of -134337552. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.99 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at -1.263 whereas that against EBITDA is 0.362.
Stock Price History:
The Beta on a monthly basis for SAGE is 0.92, which has changed by -0.73293096 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, SAGE has reached a high of $27.67, while it has fallen to a 52-week low of $4.62. The 50-Day Moving Average of the stock is 20.57%, while the 200-Day Moving Average is calculated to be -23.35%.
Shares Statistics:
For the past three months, SAGE has traded an average of 1.52M shares per day and 3727790 over the past ten days. A total of 61.17M shares are outstanding, with a floating share count of 52.70M. Insiders hold about 13.85% of the company’s shares, while institutions hold 85.20% stake in the company. Shares short for SAGE as of 1735603200 were 4832108 with a Short Ratio of 3.17, compared to 1732838400 on 6525432. Therefore, it implies a Short% of Shares Outstanding of 4832108 and a Short% of Float of 8.9499995.
Earnings Estimates
The dynamic stock of Sage Therapeutics Inc (SAGE) is currently attracting attention from 10.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.16, with high estimates of -$0.86 and low estimates of -$1.54.
Analysts are recommending an EPS of between -$5.97 and -$6.72 for the fiscal current year, implying an average EPS of -$6.4. EPS for the following year is -$3.62, with 10.0 analysts recommending between -$1.04 and -$5.09.
Revenue Estimates
A total of 16 analysts believe the company’s revenue will be $14.11M this quarter.It ranges from a high estimate of $17.4M to a low estimate of $10.35M. As of the current estimate, Sage Therapeutics Inc’s year-ago sales were $77.97MFor the next quarter, 16 analysts are estimating revenue of $15.73M. There is a high estimate of $22M for the next quarter, whereas the lowest estimate is $8.23M.
A total of 19 analysts have provided revenue estimates for SAGE’s current fiscal year. The highest revenue estimate was $45.8M, while the lowest revenue estimate was $38.78M, resulting in an average revenue estimate of $42.27M. In the same quarter a year ago, actual revenue was $86.45MBased on 19 analysts’ estimates, the company’s revenue will be $94.1M in the next fiscal year. The high estimate is $174.1M and the low estimate is $38.64M.
